Company Description
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.
The company operates through Life Science and Clinical Diagnostics segments.
The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.
It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety.
This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories.
The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market.
This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market.
It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories.
In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.
The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers.
Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Country | United States |
IPO Date | Feb 27, 1980 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 7,700 |
CEO | Norman D. Schwartz |
Contact Details
Address: 1000 Alfred Nobel Drive Hercules, California United States | |
Website | https://www.bio-rad.com |
Stock Details
Ticker Symbol | BIO |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000012208 |
CUSIP Number | 090572207 |
ISIN Number | US0905722072 |
Employer ID | 94-1381833 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Norman D. Schwartz | Chairman & Chief Executive Officer |
Jonathan P. DiVincenzo | President & Chief Operating Officer |
Roop K. Lakkaraju CPA | Executive Vice President & Chief Financial Officer |
Colleen Corey | Executive Vice President of Global Human Resources |
Courtney C. Enloe | Executive Vice President, General Counsel & Secretary |
Lee Boyd | Senior Vice President of Global Commercial Operations - Asia Pacific |
Matthew Werner | Senior Vice President and Chief Compliance & Privacy Officer |
Michael Crowley | Executive Vice President of Global Commercial Operations |
Tania DeVilliers | Senior Director, Corporate Controller & Interim Principal Accounting Officer |
Yong Chung | Vice President of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 25, 2024 | 4 | Filing |
Oct 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 22, 2024 | 4 | Filing |
Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |